Recent Updates
Recently added Catalysts
LGVN Positive Sentiment Score: 70/100

Longeveron to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Monday, June 9, 2025 2 min read
Key Takeaway: Longeveron Inc. (NASDAQ: LGVN) announced its participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, scheduled for June 16-17, 2025. CEO Wa'el Hashad will present a pre-recorded session available on June 16. The conference aims to highlight the company’s innovative cellular therapies for chronic aging-related conditions. Longeveron's investigational product, laromestrocel, is addressing significant unmet medical needs and has received multiple FDA designations, enhancing its potential in the market.

Market Sentiment Analysis

POSITIVE FACTORS

  • Longeveron is actively participating in a notable industry conference.
  • The company is gaining visibility by presenting its regenerative therapies.
  • CEO Wa'el Hashad will share important updates on the company's progress.
  • Longeveron's lead product, laromestrocel, has received multiple FDA designations.

Full Press Release Details

MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025.
Details for the Company’s corporate presentation:
Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ET
Longeveron presentation webcast link: Click Here
The webcast for this conference presentation may be accessed at the “Events and Presentations” section of the Company’s website. A replay of the webcast will be available on the Longeveron website for 90 days following the conference.
About Longeveron Inc.
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.
Investor and Media Contact:
Investor Relations Advisory Solutions
derek.cole@iradvisory.com

Tags

regenerative medicine
virtual presentation

Frequently Asked Questions

When will Longeveron present at the H.C. Wainwright Conference?

Longeveron will present at the conference on June 16-17, 2025.

What is the main product developed by Longeveron?

Longeveron's lead product is laromestrocel (Lomecel-B™), a stem cell therapy.

What conditions is Longeveron targeting with its therapies?

Longeveron targets hypoplastic left heart syndrome, Alzheimer's, and frailty.

How long will the conference webcast be available?

The webcast replay will be available for 90 days after the conference.

What designations has laromestrocel received from the FDA?

Laromestrocel has received multiple FDA designations, including Orphan Drug.

Tags: LGVN Viatris Investor Conferences Healthcare Longeveron regenerative medicine laromestrocel H.C. Wainwright
Last updated: Jun 9, 2025